Literature DB >> 15540238

Acceptance of tamoxifen chemoprevention by physicians and women at risk.

Andrew McKay, Steve Latosinsky, Wanda Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15540238     DOI： 10.1002/cncr.20744

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

Review 1.  Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  Mary E Ropka; Jess Keim; John T Philbrick
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Authors:  Laura Reimers; Katherine D Crew
Journal:  Curr Breast Cancer Rep       Date:  2012-09-01

3.  Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.

Authors:  Bilge Aktas; Mia Sorkin; Lajos Pusztai; Erin W Hofstatter
Journal:  Eur J Cancer Prev       Date:  2016-01       Impact factor: 2.497
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.